Poseida Therapeutics, Inc.

Informe acción NasdaqGS:PSTX

Capitalización de mercado: US$276.3m

Poseida Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kristin Yarema

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO14.7%
Permanencia del CEOless than a year
Participación del CEOn/a
Permanencia media de la dirección2.4yrs
Promedio de permanencia en la Junta Directiva3.1yrs

Actualizaciones recientes de la dirección

Recent updates

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kristin Yarema en comparación con los beneficios de Poseida Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$109m

Dec 31 2023US$3mUS$381k

-US$123m

Compensación vs. Mercado: La compensación total de Kristin($USD2.58M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.52M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Kristin con los resultados de la empresa.


CEO

Kristin Yarema (53 yo)

less than a year

Permanencia

US$2,581,106

Compensación

Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Mark Gergen
Executive Chairman of the Board6.4yrsUS$3.82m0.15%
$ 414.7k
Kristin Yarema
Presidentless than a yearUS$2.58msin datos
Johanna Mylet
Chief Financial Officer3.9yrssin datos0.073%
$ 202.2k
Loren Wagner
Chief Operations Officer2.4yrssin datossin datos
Kristin Martin
Chief People & Administration Officer5.4yrssin datossin datos
Alexander Chapman
Senior VP of Investor Relations & Corporate Communicationsless than a yearsin datossin datos
Harry Leonhardt
General Counsel3.9yrsUS$978.34k0.041%
$ 112.1k
Devon Shedlock
Chief Scientific Officer of Cell Therapy4.3yrssin datossin datos
Lisa Portale
Senior Vice President of Regulatory Affairs2.7yrssin datossin datos
Jeffrey W. Winkelman
Senior VP & Chief Patent Counsel2.4yrssin datossin datos
Karen Basbaum
Senior Vice President of Business Development2.4yrssin datossin datos
Syed Rizvi
Chief Medical Officerless than a yearsin datossin datos

2.4yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PSTX se considera experimentado (2.3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Mark Gergen
Executive Chairman of the Board6.4yrsUS$3.82m0.15%
$ 414.7k
Kristin Yarema
Presidentless than a yearUS$2.58msin datos
John Schmid
Lead Independent Director5.9yrsUS$175.11k0.020%
$ 56.0k
Carl June
Chairman of Cell Therapy Scientific Advisory Board3.3yrssin datossin datos
George Church
Chairman of Gene Therapy Scientific Advisory Board1.9yrssin datossin datos
Marcea Lloyd
Independent Director5.4yrsUS$149.11k0.031%
$ 84.5k
Cynthia Collins
Independent Director2.9yrsUS$155.28k0.020%
$ 56.0k
Charles Baum
Independent Director2.1yrsUS$150.28k0.014%
$ 37.3k
Luke Corning
Independent Director3.5yrsUS$140.11k0.020%
$ 56.0k
Luca Gattinoni
Member of Scientific Advisory Board3.1yrssin datossin datos
Christine Brown
Member of Scientific Advisory Board3.1yrssin datossin datos
Jan Joseph Melenhorst
Member of Scientific Advisory Board3.1yrssin datossin datos

3.1yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de PSTX se considera experimentada (3 años de antigüedad promedio).